Neeraj Agarwal, MD, FASCO

Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Truly humbled by the support of colleagues across the American Society of Clinical Oncology (@ASCO) global community. Thank you for the trust and encouragement—I’m deeply grateful and excited to serve. @OncoAlert @urotoday @OncBrothers @montypal @DrChoueiri @DrRanaMcKay

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit https://t.co/4riSVk7AQy to learn more about the candidates and place your vote! Thank you!!

[Petros Grivas @PGrivasMDPhD]

Fantastic talk by @weoncologists @OncoAlert on the role of social media in oncology education & global reach! @karima_oualla @NaglaAKarimMD @rarengan @gbanna74 @Uromigos @DrOmarMian @Panos_Vlach @tompowles1 @brian_rini @montypal @neerajaiims @IMyrtaly @BradMcG04 @bergsa83

[Miguel Zugman, MD @mzugman]

Not too late to share our @ASCO Ed Book chapter on practical aspects of tumor sequencing in clinical practice.

As an integral component of modern oncology care, ensuring that genomic profiling informs meaningful clinical decisions is more important than ever.

[Vivek Subbiah, MD @VivekSubbiah]

🚨Hot off the press- Pre-proof vesion👉Pleased to share our Editorial in @myESMO flagship journal @Annals_Oncology 👉"Next-Generation Sequencing Consensus Guidelines for Sarcoma: Progress, Gaps, and the Path Forward" 🎯🧬
👉Dr. @Dr_R_Kurzrock & I opine that👉 " Consensus must accelerate our field, not delay it. For many sarcomas, genomics isn't ancillary, it IS the DIAGNOSIS".
👉Huge congrats to @Annals_Oncology for its exceptional leadership in the field standing as one of oncology's most highly cited journals (IF 80+) @tompowles1 @FAndreMD @DrChoueiri @OncoAlert
Link: https://t.co/BKqwt5OvII

[Yüksel Ürün @DrYukselUrun]

Bladder cancer treatment is moving earlier!
🇪🇺 European Commission approved perioperative EV+pembro for cisplatin-ineligible resectable MIBC, based on EV-303: EFS and OS improved vs surgery alone. @OncoAlert @OpenMedicineHQ @MedwatchKate @Uromigos @tompowles1

[UroToday.com @urotoday]

POSEIDON meta-analysis re-examines the role of ADT with salvage radiation for #Prostate cancer. @AmarUKishan @UCLAHealth joins @neerajaiims @huntsmancancer to discuss the POSEIDON meta-analysis which pooled individual patient data from 6,057 patients across six randomized trials with nine-year median follow-up. #WatchNow > https://t.co/GD3AX2Nzp6

[UroToday.com @urotoday]

TALAPRO-3 trial results for talazoparib plus enzalutamide in HRR-mutant #mHSPC. @neerajaiims @huntsmancancer joins @zklaassen_md @GACancerCenter to discuss TALAPRO-3, a 599-patient phase 3 trial randomizing HRR-mutated metastatic hormone-sensitive prostate cancer patients to ADT plus enzalutamide plus talazoparib versus ADT plus enzalutamide plus placebo. #WatchNow on UroToday > https://t.co/Y5tJQkI8qH

[Petros Grivas @PGrivasMDPhD]

Mentorship is big part of our academic mission! So proud to see continuous growth of @LDiamantMD who is ready for training in Nuclear Medicine after a great pathway as research scholar @fredhutch @UWMedicine medicine & oncology
@DRBakaloudiMD @DMakrakisMD @montypal @PavlosMsaouel

[Alan Tan @alantanmd]

With PARP now moving into upfront mAPMN/S (metastatic Androgen Pathway Modulator Naive or Sensitive)setting - TALAPRO3, AMPLITUDE

these insights by @AzadOncology @neerajaiims are so relevant. The first 3-4m of starting PARP are so crucial in monitoring anemia, and nadir of counts. Also, don’t forget that the prostate cancer itself can cause anemia, and reducing dose too early might be the wrong move.

[UroToday.com @urotoday]

Selective PARP1 inhibition combined with ARPIs under investigation in the PETRANHA in #mHSPC. @AzadOncology @PeterMacCC sits down with @neerajaiims @huntsmancancer reporting PETRANHA phase I-II results combining saruparib, a selective PARP1 inhibitor at 60 milligrams daily, with ADT and ARPIs in metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/pYlKvE4J25

[UroToday.com @urotoday]

PTEN as a prognostic marker and clinical decision tool in #mHSPC: Multidisciplinary discussion. @Daniel_J_George, Neal Shore, MD, FACS, David Morris, MD, FACS & @neerajaiims review the CAPItello-281 Phase III trial, highlighting PTEN loss as a critical prognostic marker identifying a high-risk subset of patients with metastatic hormone-sensitive #ProstateCancer. #WatchNow > https://t.co/dHnEObn4FL

[UroToday.com @urotoday]

Genomic classifiers and AI for personalizing #ProstateCancer radiation therapy. @drjefstathiou @MassGenBrigham joins @neerajaiims @huntsmancancer to discuss the use of genomic classifiers and AI-based tools in personalizing radiation therapy for prostate cancer. #WatchNow on UroToday > https://t.co/WSgUZx48Eg #APCCC26 @Decipher_VCYT @APCCC_Lugano @arteraAI

[UroToday.com @urotoday]

FDA approval of capivasertib with abiraterone and prednisone in PTEN-deficient androgen pathway modulation-naïve or -sensitive #ProstateCancer. @neerajaiims @huntsmancancer hosts an expert panel discussion with @EHeath4100 @MayoClinic, @hoperugo @cityofhope, and @Daniel_J_George @DukeCancer on the CAPItello-281 trial. #WatchNow > https://t.co/vb4Rek0EMj @AstraZeneca

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Huge congrats to both of you @NazliDizman @montypal 👉Nazli has earned every bit of her remarkable success & has emerged as one of the rising stars in our field. Monty, this post perfectly captures what outstanding mentorship looks like. Your investment in trainees, your humility, and your ability to help others reach their full potential have left a lasting mark on our field. The best is yet to come!

[Sumanta K. Pal, MD, FASCO @montypal]

A message to @NazliDizman:

Today you will graduate from your #oncology fellowship at @UTMDAnderson. The picture below is from the 2016 @myESMO meeting in Copenhagen just after you started with my group at @cityofhope. You were my first postdoctoral fellow, and honestly, I didn't know what the heck I was doing when it came to mentoring you. The fortunate thing is you were a self starter & made my job incredibly easy, paving a clear path not just for yourself but for the trainees that came after. It's been a joy to see all that you have accomplished - publishing in @NatureMedicine, @TheLancetOncol, @JCO_ASCO & other top tier journals, getting amazing young investigator grants from @ASCO, @KidneyCancer & more & racking up more @ConquerCancerFd Merit Awards than any other trainee in recent memory (maybe tied with @crisbergerot?). Along the way, you've kept a humility & kindness about you that is unmatched, always willing to lend a hand to your junior colleagues. Your road has not been an easy one, coming from tumultuous times abroad to @cityofhope, then to @YaleIMed and then to @UTMDAnderson, but this arduous road has equipped you well for your first faculty position at @DanaFarber. I am so proud to see you join a group of oncology luminaries at @Harvard (@DrChoueiri, @KimmieNgMD, @stolaney1, @mishabeltran & so many others!!) - I am confident your stellar trajectory will continue further with their support. Enjoy Boston and know that you will always have support & good vibes coming from the west coast.

All the best,

#WorkDad

[Pavlos Msaouel @PavlosMsaouel]

1/5 🧵 New paper out today in the @SNM_MI Journal of Nuclear Medicine: FDG PET/CT may change how we stage #RenalMedullaryCarcinoma (RMC) and help patients get the right treatment faster: https://t.co/7ebeFvw95M #endRMC #MsaouelLab

[OncLive.com @OncLive]

EZH2 is overexpressed in most CRPC, but its role goes beyond simple gene silencing. Neeraj Agarwal, MD, and Alicia Morgans, MD, MPH, explain how its non-canonical AR co-activation may drive ARPI resistance.

Explore the OncLive® Insights series: https://t.co/oDg2cwbee3

@neerajaiims @huntsmancancer @CaPsurvivorship @DanaFarber #ProstateCancer #EZH2 #mCRPC

[UroToday.com @urotoday]

Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo

[Toni Choueiri, MD @DrChoueiri]

Today is world #kidneycancer day! We have made lots of progress in all stages, but so much work still to do!

#kcsm @kidneycan @DanaFarber_GU

[Dr Amol Akhade @SuyogCancer]

Excellent slides about definition of endocrine resistance and sequencing of endocrine therapy in 2026. From the talk by @AlexEniu @asco #asco26 🙂👍. Money 💰 Slides .

[Sumanta K. Pal, MD, FASCO @montypal]

Kudos to the phenomenal team on these impactful publications in @CircAHA & @JCO_ASCO, two of the premier journals in #cardiology & #oncology, respectively! I had the pleasure of meeting with @avirupguha through his collaboration with @neerajaiims - impressive to see these joint efforts maturing over the years & getting synthesized into useful, practical guidance for trial design. Particularly like the figure below, which distills in the lower panel how to integrate various CV endpoints.